Malignant Neoplasm of Unknown Primary — Research

Malignant Neoplasm of Unknown Primary — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-11	1,145	`("Malignant Neoplasm of Unknown Primary"[tiab] OR "Cancer of Unknown Primary"[tiab] OR "Cancer of Unknown Primary Site"[tiab] OR "cancer of unknown primary origin"[tiab] OR "Metastatic Malignant Neoplasm of Unknown Primary Origin"[tiab])`	2026-09-11	pubmed
Last 5 years	2021-01-01 → 2026-12-31	520	`("Malignant Neoplasm of Unknown Primary"[tiab] OR "Cancer of Unknown Primary"[tiab] OR "Cancer of Unknown Primary Site"[tiab] OR "cancer of unknown primary origin"[tiab] OR "Metastatic Malignant Neoplasm of Unknown Primary Origin"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-11	pubmed
Last 12 months	2025-09-11 → 2026-09-11	95	`("Malignant Neoplasm of Unknown Primary"[tiab] OR "Cancer of Unknown Primary"[tiab] OR "Cancer of Unknown Primary Site"[tiab] OR "cancer of unknown primary origin"[tiab] OR "Metastatic Malignant Neoplasm of Unknown Primary Origin"[tiab]) AND (2025/09/11:2026/09/11[dp])`	2026-09-11	pubmed

Data updated 20 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (486)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 151–175 of 486 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
· J Clin Oncol · 2017 · PMID 27870574 · validated civic_curation pubmed
GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.
· J Transl Med · 2016 · PMID 27154293 · validated civic_curation pubmed
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
· Breast Cancer Res Treat · 2011 · PMID 21594665 · validated civic_curation pubmed